| Heading: |
Rare Diseases: Drugs |
| Question ID: |
1806422 |
| UIN: |
54852 |
| House: |
Commons |
| Date tabled: |
2025-05-30 |
| Asking Member ID: |
4397 |
| Asking Member display name: |
Peter Dowd
|
| Asking Member handle: |
peter_dowd
|
| Asking Member Twitter reference: |
@peter_dowd
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of suspending the medicines repurposing programme on people affected by rare conditions. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
In April 2025, a decision was made to suspend the national Medicines Repurposing Programme. The decision was made with consideration to the following factors: The programme team and partners have learned that there are fewer repurposing opportunities in p... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |